Network pharmacology-based study of the protective mechanism of conciliatory anti-allergic decoction on asthma

Main Article Content

Xiaobo Xuan
Ziyan Sun
Chenhuan Yu
Jian Chen
Mei Chen
Qili Wang
Lan Li

Keywords

Asthma, Conciliatory anti-allergic decoction, Active ingredients, Targets, Pro-inflammatory cytokines, Pathways

Abstract

Background: This study aimed to explore the underlying anti-asthma pharmacological mechanisms of conciliatory anti-allergic decoction (CAD) with a network pharmacology approach.


Methods: Traditional Chinese medicine-related databases were utilized to screen the active ingredients of CAD. Targets of CAD for asthma treatment were also identified based on related databases. The protein-protein interaction network, biological function and KEGG pathway enrichment analysis, and molecular docking of the targets were performed. Furthermore, an asthma mouse model experiment involving HE staining, AB-PAS staining, and ELISA was also performed to assess the anti-asthma effect of CAD.


Results: There were 77 active ingredients in CAD, including quercetin, kaempferol, stigmasterol, luteolin, cryptotanshinone, beta-sitosterol, acacetin, naringenin, baicalin, and 48 related targets for asthma treatment, mainly including TNF, IL4, IL5, IL10, IL13 and IFN-, were identified with ideal molecular docking binding scores by network pharmacology analysis. KEGG pathway analysis revealed that these targets were directly involved in the asthma pathway, Th1 and Th2 cell differentiation, and signaling pathways correlated with asthma (NF-B, IL17, T cell receptor, TNF, JAK-STAT signaling pathways, etc.). Animal experiments also confirmed that CAD could attenuate inflammatory cell invasion, goblet cell hyperplasia and mucus secretion. The levels of the major targets TNF-, IL4, IL5, and IL13 can also be regulated by CAD in an asthma mouse model.


Conclusion: The anti-asthma mechanism of CAD possibly stemmed from the active ingredients targeting asthma-related targets, which are involved in the asthma pathway and signaling pathways to exhibit therapeutic effects.

Abstract 69 | PDF Downloads 116

References

1. Ahmed R, Robinson R, Mortimer K. The epidemiology of noncommunicable respiratory disease in sub-Saharan Africa, the Middle
East, and North Africa. Malawi Med. 2017;29:203-11.

2. Amato DG, Cagnani CE, Cecchi L, et al. Climate change, air pollution and extreme events leading to increasing prevalence of allergic respiratory diseases. Multidiscip Respir Med. 2013;8:12.

3. Pond Z, Burke H, Duffus C, et al. Rising to the GINA Asthma Challenge: thinking beyond just asthma. Eur. Respir. J. 2012;40:280-1.

4. Pinja I, Tuomisto LE, Hannu K. Phenotypes, risk factors, and mechanisms of adult-onset asthma. Mediators Inflamm.
2015;2015:1-19.

5. Tan HT, Sugita K, Akdis CA. Novel biologicals for the treatment of allergic diseases and asthma. Curr. Allergy Asthma Rep.
2016;16:70.

6. Quirce S, Bobolea I, Barranco P. Emerging drugs for asthma. Expert Opin Emerg Drugs. 2012;17:219-37.

7. Kruse RL, Vanijcharoenkarn K. Drug repurposing to treat asthma and allergic disorders: progress and prospects. Allergy. 2018;73:313-22.

8. Zheng XY, Song SD, Hong YY, et al. Effect of roflumilast and zileuton on the contraction of airway smooth muscle of asthmatic rat. Chin J Mod Appl Pharm. 2019;36:269-73.

9. Li XM. Traditional Chinese herbal remedies for asthma and food allergy. J. Allergy Clin. Immunol. 2007;120:25-31.

10. Kaixian C. Precision medicine and innovative development of traditional Chinese medicine (TCM), modernization of Traditional Chinese Medicine and Materia Medica. World Sci Technol. 2017;19:7-18.

11. Li L, Chen H, Chen J, et al. Effect of Chinese medication on the immune function and chronic airway inflammation in asthma children at chronic duration stage. J Trad Chin Med. 2012;53:2011-3.

12. Song W, Ni S, Fu Y, et al. Uncovering the mechanism of Maxing Ganshi Decoction on asthma from a systematic perspective: a network pharmacology study. Sci Rep. 2018;8:17362.

13. Liu J, Xiong H, Cheng Y, et al. Effects of taraxasterol on ovalbumin-induced allergic asthma in mice. J. Ethnopharmacol. 2013;148:787-93.

14. Yang X, Li Y, He Y, et al. Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process. Int. Immunopharmacol. 2015;26:401-8.

15. Park HJ, Lee CM, Jung ID, et al. Quercetin regulates Th1/Th2 balance in a murine model of asthma. Int. Immunopharmacol. 2009;9:261-7.

16. Gong JH, Shin D, Han SY, et al. Kaempferol suppresses eosionphil infiltration and airway inflammation in airway epithelial cells and in mice with allergic asthma. J. Nutr. 2012;142:47-56.

17. Sun J, Li LL, Wu JF, et al. Effects of baicalin on airway remodeling in asthmatic mice. Planta Med. 2013;79:199-206.

18. Opoku AA, Darko OD, Newman O. Stigmasterol modulates allergic airway inflammation in guinea pig model of ovalbumin-induced asthma. Mediators Inflamm. 2017:1-11.

19. Ryu EK, Kim TH, Jang EJ, et al. Wogonin, a plant flavone from Scutellariae radix, attenuated ovalbumin-induced airway inflammation in mouse model of asthma via the suppression of IL-4/STAT6 signaling. J Clin Biochem Nutr. 2015;57:105-12.

20. Spiropoulos K, Karkoulias K, Kaparianos A, et al. Role and pharmacogenomics of TNF-alpha in asthma. Mini Rev. Med. Chem.
2008;8:934-42.

21. Berry M, Brightling C, Pavord I, et al. TNF-alpha in asthma. Curr. Opin. Pharmacol. 2007;7:279-82.

22. Kobayashi M, Ashino S, Shiohama Y, et al. IFN- elevates airway hyper-responsiveness via up-regulation of neurokinin A/neurokinin-2 receptor signaling in a severe asthma model. Eur. J. Immunol. 2012;42:393-402.

23. Wegmann M. Th2 cells as targets for therapeutic intervention in allergic bronchial asthma. Expert Rev. Mol. Diagn. 2009;9:85-100.

24. Walsh GM. Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma -an update. Expert Rev Clin Immunol.
2017;13:143-9.

25. Walsh GM. Recent developments in the use of biologics targeting IL-5, IL-4 or IL-13 in severe refractory asthma. Expert Rev Respir Med. 2018;2:957-63.

26. Wang NN, Tong YL, Liu X, et al. Establishment of a high throughput drug screening cell inflammatory model based on NF-B signaling pathway. Chin J Mod Appl Pharm. 2019;36:397-402.

27. Zhou QL, Wang TY, Li M. Alleviating airway inflammation by inhibiting ERK-NF-B signaling pathway by blocking Kv1.3 channels.
PLoS ONE. 2018;13:e0199167.

28. Zhang B, Pei Z, Yinan Y, et al. Deguelin attenuates allergic airway inflammation via inhibition of NF-b pathway in mice. Int
J Biol Sci. 2017;13:492-504.

29. O’Connell D, Bouazza B, Kokalari B, et al. IFN--induced JAK/STAT, but not NF-B, signaling pathway is insensitive to glucocorticoid in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2015;309:L348-59.